Coronary angiography has been the gold standard for assessing coronary artery disease and guiding interventions. Because of its reproducibility, quantitative angiography (QCA) has introduced objectivity and consistency into clinical trials. However, angiography is only a lumenogram. Therefore, it has two major limitations: atherosclerosis is a disease of the arterial wall compromising the lumen only in its late stages; and angiography provides only a shadowgraphic representation of complex three dimensional coronary lumen anatomy.
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To overcome some of these limitations, new imaging modalities such as intravascular ultrasound (IVUS) that is unique to tomographic imaging and, in coronary arteries, unique to IVUS. The residual plaque burden may act as an amplifier of the remodelling process, the major mechanism of restenosis in non-stented lesions.'2 Thus, it is important to obtain not only the largest possible lumen, but also the lowest residual plaque burden. The predictive value of this parameter has been substantiated in phase II of the GUIDE Trial (blinded postintervention IVUS imaging) and in two IVUS guided direction coronary atherectomy trials (OARS (Optimal Atherectomy Restenosis Study) and ABACAS (Adjunct Balloon Angioplasty Coronary Atherectomy Study)) in which restenosis rates tracked the residual plaque burdens.13 14 
FINAL DIMENSIONS
Some patients do have good long term results after conventional PTCA. Unfortunately, angiography does not predictably identify them ( fig 5) . As with the pre-intervention assessment of lumen dimensions, the correlation between IVUS and QCA is only fair; this also true for patients treated with stents and high pressure PTCA (fig 1) . Our IVUS end points for stent implantation in native coronary arteries are: minimum stent cross sectional area > 80% of the reference lumen cross sectional area or an absolute minimum stent cross sectional area > 7 0 mm2; and complete stent-vessel wall apposition. Even after routine high pressure (> 16 atm) adjunct PTCA, 40% of cases require additional balloon inflations (higher pressures or larger sizes) to achieve these end points. If these IVUS end points are met, the clinical restenosis rate is approximately 10%, regardless of patient, lesion, or treatment characteristics (number of stents, pre-stent use of atheroablative devices, etc)'5; this is significantly lower than if these end points are not met. For example, aorto-ostial stent placement is often technically challenging. IVUS identifies proper stent placement v misplacement (in which the stent does not cover the aorto ostial junction but slips into the proximal vessel).
COMPLICATIONS
Complications during interventional procedures are a reality. Dissections are detected by IVUS twice as often as by angiography ( fig 5) ; however, it is important to note that dissections behind calcium are shadowed by the calcium and, therefore, will not be seen by IVUS. Similarly, vessel perforations after directional coronary atherectomy and deep wall haematomas may be detected only by IVUS.
Conclusions
Linitations to the routine incorporation of IVUS into interventional procedures are: cost, equipment clumsiness, and image interpretation. Nevertheless, based on the above findings, we have gradually evolved from a strategy of angiographic guidance of interventional procedures to IVUS guided intervention in more than 6000 patients. The use of intravascular ultrasound (IVUS), a method of imaging the wall of the coronary artery, complements the information obtained by coronary angiography, which defines the contour of the vessel lumen. IVUS demonstrates that significant mural disease is almost invariably present in angiographically normal segments of "focally" diseased coronary arteries,' and has shown obstructive disease in patients with coronary arteries judged angiographically to be normal or near normal,2 which might justify its availability, at least as a supraregional service.
IVUS has been used to guide selection of the device used for percutaneous interventional treatment of coronary lesions but it has yet to be shown that this approach influences clinical outcome, and few interventional centres offer routine pre-interventional IVUS imaging and a choice of interventional devices that includes three different atherectomy catheters and an excimer laser!3
The demonstration by IVUS that coronary stents deployed at nominal balloon pressure are usually under expanded was an invaluable contribution. 4 We now appreciate the need for optimal stent deployment, but it is unclear whether the routine use of IVUS guidance is actually essential for optimal stenting. The remarkable results obtained in the Benestent II pilot study, for example, were obtained without the routine use of this technique.5
The use of IVUS will continue to help our understanding of coronary artery disease. As it is both time consuming and expensive, widespread clinical use is not justifiable unless or until further information suggests that this significantly improves the clinical outcome of large numbers of patients.
